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Abstract
Background: Oxidative stress induced by the production of reactive oxygen species may play a
critical role in the stimulation of HIV replication and the development of immunodeficiency. This
study was conducted as there are limited and inconclusive studies on the significance of a novel
early marker of oxidative stress which can reflect the total antioxidant capacity in HIV patients,
Methods: Total antioxidant capacity (TAC) and lipid peroxidation were evaluated in 50 HIV-1
seropositive patients (including HIV-1 symptomatics and asymptomatics). Controls included 50 age
and sex matched and apparently healthy HIV-1 seronegative subjects. Serum malondialdehyde
(MDA), Total antioxidant capacity [TAC] (by ferric reducing antioxidant power assay), vitamin E,
vitamin C and superoxide dismutase (SOD) enzyme activity were estimated among controls and
cases. Statistical comparisons and correlations at 5% level of significance were determined.
Results and Discussion: The mean MDA concentrations were significantly elevated in both HIV-
1 asymptomatic (CD4+ count > 500 cells/microliter) and HIV-1 symptomatic (CD4+ count <500
cells/microliter) groups (Mean ± S.D values were 2.2 +/- 0.7 nmol/ml and 2.8 +/- 0.8 nmol/ml
respectively) when compared with the control group (Mean ± S.D value was 0.9 +/- 0.2 nmol/ml)
(p < 0.01). The mean TAC of HIV- 1 asymptomatic and HIV-1 symptomatic (Mean ± S.D values
were 754.6 ± 135.6 μmol/L and 676.6 ± 154.1 μmol/L respectively) patients were significantly
reduced compared with the control group (Mean ± S.D value was 1018.7 ± 125.6 μmol/L) (p <
0.01). Also, there were significantly decreased levels of vitamin E, vitamin C and SOD among HIV-
1 seropositive patients(controls > asymptomatic > symptomatic) compared to controls (p < 0.01).
TAC showed significant negative correlation with MDA among HIV-1 infected patients (p < 0.01).
Conclusion:  Our results clearly show that severe oxidative stress occurs in the HIV-1
seropositive patients in comparison with controls, and increases significantly with the progression
of disease, i.e. HIV-1 symptomatics > asymptomatics > controls. TAC can be used as a novel early
bio-chemical marker of oxidative stress in HIV-1 infected patients which may result in reduced
tissue damage by free radicals and help to monitor and optimize antioxidant therapy in such
patients.
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Background
HIV infection is characterized by numerical and func-
tional decline in CD4 cells, which result in progressive
immunodeficiency. Oxidative stress can be defined as an
imbalance between the oxidant and antioxidant system,
with an advantage towards the oxidant system: A variety
of enzymatic (superoxide dismutase, catalase, glutathione
peroxidase etc.) and nonenzymatic (carotenoids, toco-
pherols, ascorbate, bioflavonoids, bilirubin, uric acid etc)
antioxidants present in human serum become insufficient
to circumvent HIV-1 replication secondary to cellular ROS
production (superoxide anion, hydroxyl radical, hydro-
gen peroxide etc) by a pro-oxidant effect of inflammatory
cytokines and/or a polymorphonuclear leukocyte activa-
tion [1]. No single component of serum antioxidant com-
plex could fully reflect the protective efficiency of blood,
probably because of interactions that occur in vivo among
different antioxidant compounds. Total antioxidant
capacity (TAC) considers the cumulative effect of all anti-
oxidants present in blood and body fluids [2]. Although
previous studies have suggested a role of oxidative stress
in the stimulation of HIV replication and the develop-
ment of immunodeficiency, significance of a novel early
marker of oxidative stress which can reflect the total anti-
oxidant capacity in HIV patients is not much studied [1,2].
The purpose of the present study was to measure and com-
pare the TAC and lipid peroxidation in HIV-1 asympto-
matic and HIV-1 symptomatic patients with age matched
HIV-seronegative healthy controls and to correlate the
lipid peroxidation with antioxidant markers.
Materials and methods
This study was conducted at Sri Siddhartha Medical
Teaching Hospital and Research Centre, Tumkur. The
study included 50 cases aged >18 years, of either sex (31
men with mean age of 45.4 years and 19 women with
mean age of 36.2 years), diagnosed as HIV-1 infected
patients (confirmed by TriDot ELISA) before the com-
mencement of antiretroviral therapy and 50 age and sex
matched healthy controls. HIV-1 seropositive patients
were further classified according to the Centre for Disease
Control and Prevention (CDC) Criteria as HIV-1 asymp-
tomatic (CD4+ count > 500 cells/microliter) [n = 28] and
HIV-1 symptomatic including AIDS patients (CD4+ count
< 500 cells/microliter) [n = 22]. All subjects underwent an
initial screening that included a detailed history (medical,
smoking, diet, and alcohol and supplemental vitamin
intakes) and anthropometric (weight and height) and
biochemical (complete blood count, glucose, creatinine,
urea, and liver enzymes) measurements. Patients were eli-
gible if they had no acute opportunistic infection. Exclu-
sion criteria were as follows: smoking, patients on
antioxidant vitamin therapy before the study, hyperlipi-
demia, diabetes, kidney or liver dysfunction, intractable
diarrhea (more than six liquid stools per day), vomiting,
or evidence of gastrointestinal bleeding. The study was
conducted after informed consent was obtained and the
study has been approved by the ethical committee of Sri
Siddhartha Medical College, Tumkur.
Under aseptic precautions about 6 ml of a venous blood
sample was collected from HIV-1 patients and from
healthy controls. Blood was collected in appropriate tubes
and centrifuged at 3000 g for 15 min and the separated
serum was stored at 4°C until analysis was carried out.
Ferric reducing antioxidant power (FRAP) assay, estima-
tion of malondialdehyde (MDA), vitamin E, vitamin C
levels and SOD enzyme activity were carried out on serum
sample. All the chemicals used were of highest analytical
grade available in India. CD4+ count, CD8+ count and
CD4+/CD8+ ratio were measured by Tricolor flowcytom-
etry.
Total antioxidant capacity was measured by FRAP assay
according to the method of Benzie.F.F. and J.J.Strain [3].
At low pH, when a ferric tripyridyltriazine (Fe III-TPTZ)
complex is reduced to the ferrous (Fe II) form, an intense
blue colour with an absorption maximum at 593 nm
develops.
Serum vitamin E was estimated by Baker and Frank
method [4] and vitamin C by 2, 4 – DNPH method [5].
SOD enzyme activity was determined with the direct spec-
trophotometric method employing KO2 as previously
described by Marklund, with some modifications [6,7].
The data are presented as units per milliliter of serum.
Lipid peroxidation was measured by serum MDA estima-
tion according to the colorimetric method of Satoh.k [8].
Lipoproteins are precipitated from the specimen by add-
ing trichloroacetic acid. 0.05 M sulphuric acid and 0.67%
thiobarbituric acid (TBA) in 2 M sodium sulphate are
added to this precipitate and the coupling of lipid perox-
ide with TBA is carried out by heating in a boiling water-
bath for 30 minutes. The resulting chromogen is extracted
in n-butanol, which is measured colorimetrically at 530
nm.
Statistical analysis
Each result was expressed as mean ± standard deviation.
The statistical significance of the data were determined by
Student's t-test and one way ANOVA test at 5% level of sig-
nificance. Pearson's correlation coefficient was deter-
mined at 5% level of significance. Statistical analysis was
done using SPSS software version 16.0.
Results
There was significantly increased levels of MDA in the
HIV-1 seropositive patients (HIV-1 symptomatic > HIV-1Journal of Biomedical Science 2009, 16:61 http://www.jbiomedsci.com/content/16/1/61
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asymptomatic) compared to the control group (p < 0.01)
(Table 1) suggesting lipid peroxidation. There were signif-
icantly decreased levels of vitamin E, vitamin C, SOD
enzyme activity along with TAC in the HIV-1 seropositive
patients (Significantly decreased in HIV-1 symptomatics
compared to HIV-1 asymptomatics) compared to the con-
trol group (p < 0.01) (Table 1), suggesting antioxidant
depletion. Statistically significant negative correlations
found between TAC and MDA in both HIV-1 sympto-
matic and HIV-1 asymptomatic patients suggested oxida-
tive stress (Table 2). Our results clearly show that severe
oxidative stress occurs in the HIV-1 seropositive patients
in comparison with controls, and increases significantly
with the progression of disease, i.e. HIV-1 symptomatics >
asymptomatics > controls.
Discussion
Infection by human immunodeficiency virus (HIV)
causes persistent chronic inflammation. Viral Tat protein
plays a role in the intracellular increase of reactive oxygen
species which in turn influence the increase in the apop-
tosis index, mainly the one mediated by CD95 causing a
decrease of CD4 + T cell lymphocytes and more impor-
tantly an increase in HIV-1 replication secondary to free
radicals overproduction [9]. Under normal conditions,
the ROS produced in the course of metabolism are con-
tained by the natural antioxidant system which consists of
a series of antioxidant enzymes such as superoxide dis-
mutase (SOD), catalase, glutathione peroxidase as well as
numerous endogenous and dietary antioxidant com-
pounds that are capable of reacting with and inactivating
ROS thereby protects the functional and structural mole-
cules against ROS-mediated tissue damage [10].
MDA is a three carbon, low molecular weight aldehyde
that can be produced from free radical attack on polyun-
saturated fatty acids of biological membranes. The deter-
mination of MDA is used for monitoring lipid
peroxidation in biological samples. Previous studies show
inconsistent findings regarding MDA levels in HIV-1
infected patients (lipid peroxidation is similar between
HIV asymptomatics and HIV symptomatics) [11]. In the
present study, the significantly elevated serum MDA con-
centration in HIV-1 infected patients (HIV-1 symptomat-
ics > HIV-1 asymptomatics, in contrast to previous
studies) compared to controls correlating negatively with
TAC reflects the increased formation of ROS and lipid per-
oxidation with progressive immunodeficiency.
Vitamin E, a potent chain breaking lipid soluble antioxi-
dant, reacts with lipid peroxyl radicals eventually termi-
nating the peroxidation chain reaction and thereby
reducing oxidative damage. Vitamin C represents the
major water-soluble antioxidant in the human body. SOD
is an endogenous antioxidant that catalyses the dismuta-
tion of the superoxide anion radical [12]. There are con-
flicting reports in the values of antioxidant vitamins
(vitamin E and vitamin C) and SOD enzyme activity
among HIV-1 infected patients in various stages in the lit-
erature [11,12]. In our study, vitamin E, vitamin C, SOD
and TAC levels are decreased in HIV-1 patients (depletion
is pronounced in HIV-1 symptomatics compared to HIV-
Table 1: Comparisons of oxidants and antioxidants in HIV-1 infected patients.
Controls (MEAN ± S.D) 
N = 50
HIV-1 Asymptomatic patients 
(MEAN ± S.D) N = 28
HIV-1 Symptomatic patients 
(MEAN ± S.D) N = 22
p value
MDA (n mol/mL) 0.9 ± 0.2 2.2 ± 0.7 2.8 ± 0.8 P < 0.01
TAC (μmol/L) 1018.7 ± 125.6 754.6 ± 135.6 676.6 ± 154.1 P < 0.01
Vitamin E (mg/L) 10.0 ± 0.8 8.2 ± 0.6 7.4 ± 0.6 P < 0.01
Vitamin C (mg/dl) 6.3 ± 0.2 5.8 ± 0.2 3.6 ± 0.2 P < 0.01
SOD activity (units/ml) 8.75 ± 1.1 4.9 ± 0.4 3.7 ± 0.4 P < 0.01
MDA – Malondialdehyde, TAC – Total Antioxidant Capacity, SOD – Superoxide Dismutase.
Table 2: Correlations between oxidants and antioxidants in HIV infected patients.
HIV-1 Asymptomatic patients HIV-1 Symptomatic patients
r value p value r value p value
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1 asymptomatics, in contrast to previous studies where
there were no significant differences in antioxidant vita-
mins in both groups [11]) which is observed from HIV-1
asymptomatic stage itself.
Although the concentration of plasma antioxidant com-
ponents can be measured individually, these measure-
ments may be time- and cost-consuming and labour
intensive. In addition, it may not accurately reflect the
total antioxidant status [13]. Thus, the accurate antioxi-
dant capacity of the organism can only be determined by
the measurement of total antioxidant capacity. FRAP assay
is presented as a novel method of assessing total antioxi-
dant capacity and is considered as a useful indicator of the
body's antioxidant status to counteract the oxidative dam-
age due to ROS. The advantage of the FRAP assay is in
being fast, easy to handle, with highly reproducible results
[14]. A significantly lower serum TAC concentration in the
HIV-1 patients compared to controls reflects a lower total
antioxidant capacity. Negative correlation between MDA
and TAC in this study suggests an increased oxidative
stress in HIV-1 infected patients. This antioxidant defi-
ciency in HIV-1 seropositive populations is probably due
to depletion of antioxidant molecules when they are con-
sumed in the process of protecting cells against ROS
induced oxidative damage in a magnitude that is related
to advancement of the disease to AIDS. A weakened anti-
oxidant defense system, in turn, could lead to further
enhancement in lipid peroxidation [3,15].
In conclusion, this study showed increased lipid peroxida-
tion, measured by MDA concentrations, in HIV-1 seropos-
itive patients and decreased concentrations of individual
antioxidants and total antioxidant capacity which was evi-
dent from HIV-1 asymptomatic stage itself. The possibility
of counteracting oxidative stress by a pool of proper anti-
oxidants plus an appropriate diet, mainly in patients
whose blood antioxidant deficiencies can be easily rebal-
anced, may have real health benefit and represent a prom-
ising way of inhibiting the progression of disease. Thus,
TAC may be useful as an early marker of oxidative stress to
monitor and optimize antioxidant therapy as an adjunct
in the management of HIV-1 infected patients.
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